Claims for Patent: 8,173,172

Summary for Patent: 8,173,172

Title:	Preparation of powder agglomerates
Abstract:	The invention relates to a method of producing an agglomerate of drug and solid binder. The process involves producing individual agglomerate particles and then converting the convertible amorphous content of same, following agglomeration, by the application of, for example, moisture. Agglomerates capable of conversion as well as the finished agglomerates and oral and nasal dosing systems including same are also contemplated. The process produces agglomerates which are rugged but which will produce an acceptable fine particle fraction during dosing.
Inventor(s):	Yang; Tsong-Toh (Warren, NJ)
Assignee:	Schering Corporation (Kenilworth, NJ)
Application Number:	11/947,608
Patent Claims:	1. A uniform dry powder composition comprising crystalline agglomerates of fine particles of at least one pharmacologically active agent and particles of lactose wherein the composition has a bulk density of from about 0.29 to about 0.38 g/cm.sup.3, and wherein the composition is substantially homogeneous; wherein said at least one active agent comprises mometasone furoate. 2. A composition according to claim 1, wherein the composition has a bulk density of from about 0.31 g/cm.sup.3 to about 0.38 g/cm.sup.3. 3. A composition according to claim 1, wherein the composition has a bulk density of from about 0.35 g/cm.sup.3 to about 0.38 g/cm.sup.3. 4. A composition according to claim 1, wherein the composition has a bulk density of about 0.35 g/cm.sup.3. 5. A composition according to claim 1, wherein the mometasone furoate and lactose particles have a particle size of less than about 10 .mu.m. 6. A composition according to claim 1, wherein the mometasone furoate particles and lactose particles have a particle size of from about 5 .mu.m to about 10 .mu.m. 7. A composition according to claim 1, wherein the mometasone furoate particles and lactose particles have a particle size of from about 5 .mu.m to about 6.8 .mu.m. 8. A composition according to claim 1, wherein the mometasone furoate particles and lactose particles have a particle size of about 4.7 .mu.m. 9. A composition according to claim 1, wherein the mometasone furoate and lactose particles have a particle size of less than 6.8 .mu.m. 10. A composition according to claim 1, wherein the mometasone furoate is anhydrous mometasone furoate. 11. A composition according to claim 1, wherein the lactose is anhydrous lactose. 12. A composition according to claim 1, wherein the lactose is hydrous lactose. 13. A composition according to claim 1, wherein the agglomerates have an average size of from about 300 .mu.m to about 1000 .mu.m. 14. A composition according to claim 1, wherein the agglomerates have a average size of from about 400 .mu.m to about 700 .mu.m. 15. A composition according to claim 1, wherein the agglomerates have a average size of from about 500 .mu.m to about 600 .mu.m. 16. A uniform dry powder composition comprising agglomerates having an average size of from about 300 .mu.m to about 1000 .mu.m; said agglomerates comprising fine particles of mometasone furoate and particles of lactose wherein the composition has a bulk density of from about 0.29 to about 0.38 g/cm.sup.3, and wherein the composition is substantially homogeneous. 17. A composition according to claim 16, wherein the agglomerates have a average size of from about 500 .mu.m to about 600 .mu.m. 18. A composition according to claim 16, wherein the powder comprises crystalline agglomerates. 19. A uniform dry powder composition comprising agglomerates having an average size of from about 300 .mu.m to about 1000 .mu.m; said agglomerates comprising fine particles of at least one pharmacologically active agent comprising mometasone furoate and particles of lactose wherein the composition has a bulk density of from about 0.29 to about 0.38 g/cm.sup.3, and wherein the composition is substantially homogeneous. 20. A composition according to claim 19, wherein the agglomerates have a average size of from about 500 .mu.m to about 600 .mu.m. 21. A composition according to claim 19, wherein the powder comprises crystalline agglomerates. 22. A process for preparing a uniform dry powder composition comprising crystalline agglomerates of fine particles of one pharmacologically active agent which is mometasone furoate and particles of lactose wherein the composition has a bulk density of from 0.29 to 0.38 g/cm.sup.3 and the composition is substantially homogeneous, the process comprising: (a) micronizing particles of mometasone furoate and particles of lactose, so that at least one of the mometasone furoate and the lactose has a preselected amount of convertible amorphous content which is capable of being converted to crystalline form upon exposure to a preselected stimulus, the convertible amorphous content being provided in an amount which is sufficient to allow for the formation of agglomerates; (b) agglomerating the particles of mometasone furoate and lactose while maintaining the preselected amount of convertible amorphous content; and (c) exposing the convertible amorphous content within the agglomerates to the preselected stimulus to convert the convertible amorphous content to a crystalline form. 23. A process according to claim 22 wherein the stimulus is an atmosphere having a humidity sufficient to cause substantially complete conversion of the convertible amorphous content within the agglomerates to a crystalline form. 24. A composition according to claim 22, wherein the agglomerates have an average size of from about 300 .mu.m to about 1000 .mu.m. 25. A process for preparing a uniform dry powder composition comprising agglomerates of fine particles of one pharmacologically active agent which is mometasone furoate and particles of lactose wherein the composition has a bulk density of from 0.29 to 0.38 g/cm.sup.3 and the composition is substantially homogeneous, the process comprising: micronizing particles of mometasone furoate and particles of lactose to obtain micronized mometasone furoate particles and lactose particles, wherein at least one of mometasone furoate and the lactose has a convertible amorphous content; mixing the micronized mometasone furoate particles and lactose particles to obtain a substantially homogenous mixture, and agglomerating the mixture and maintaining the convertible amorphous content; and spheronizing the agglomerates, and exposing the convertible amorphous content within the agglomerates to an atmosphere having a humidity sufficient to cause substantially complete conversion of the convertible amorphous content within the agglomerates to a crystalline form.